A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial...
Pfizer
Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2...
